Articles by Zachary Bessette
Additional analyses from the CheckMate 9DW study shed further light on the clinical efficacy and safety of ipi/nivo for uHCC.
Results of NIR-B trial sheds light on the clinical utility of niraparib in patients with BRCA-mutated GI cancers.
A novel auto-segmentation model and radiomics signature may help with preoperative clinical decision-making for GEP-NETs.
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
The addition of preop CRT to periop chemo may not have added OS benefit for patients with resectable G/GEJ adenocarcinoma.
Cabozantinib continues to demonstrate significant improvement in PFS in extra-pancreatic or pancreatic neuroendocrine tumors.
Amivantamab plus chemo shows encouraging and durable antitumor activity for anti-EGFR-naïve RAS/RAF wild-type mCRC.
FDA approval comes after the IMscin001 trial, an open-label, multi-center, international analysis of adult patients.
The CodeBreaK 101 study assessed the safety and efficacy of soto, pani, and FOLFIRI for KRAS G12C-mutated mCRC.
STRIDE shows “unprecedented” 5-year survival benefit, with no additional serious safety events, for patients with uHCC.
These data may support the approval of pembro plus trastuzumab and chemo in patients with HER2+ metastatic G/GEJ cancer.
The latest data from the RECAST trial shed light on FOLFIRI plus RAM for patients with metastatic CRC.
A phase 2 trial comparing DEB-TACE with irinotecan, mitomycin C vs DEB-TACE with doxorubicin for intermediate-stage HCC.
FOLFOX-HAIC plus sintilimab and IBI305 demonstrates promising safety and efficacy in uHCC, Child-Pugh B liver function.
The FDA's decision to accept the sBLA is based on the encouraging results of the phase 3 CheckMate-9DW study.
Integrated PET/MRI may be superior to PET/CT in diagnosing malignant tumor liver metastasis/lymphoma hepatic infiltration.
Neoadjuvant pembrolizumab may be effective and safe for early-stage dMMR/MSI-high colorectal cancer.
The ORCHESTRA trial does not support additional tumor debulking to improve OS for patients with multiorgan mCRC.
Thermal ablation may offer shorter hospital stay and improved local control for small-size colorectal liver metastases.
A phase 3 study offers valuable insights into the dynamic landscape of neoadjuvant therapy for LARC management.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.